Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment

Completed

Conditions: Breast Cancer

First Posted Date: 2014-12-30

Last Posted Date: 2020-09-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1334

Registration Number: NCT02326857

Locations: 🇲🇽
Instituto Jalisciense de Cancerologia, Guadalajara, Mexico
🇧🇷
Instituto do C(SqrRoot) ncer do Estado de S(SqrRoot) o Paulo, Sao Paulo, Brazil
🇲🇽
Universidad de Guadalajara, Guadalajara, Mexico

and more 6 locations

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

Phase 2

Terminated

Conditions: Chronic Graft vs. Host Disease
Graft vs Host Disease
Graft-Versus-Host Disease

Interventions: Procedure: Extracorporeal Photopheresis (ECP)
Drug: Methoxsalen

First Posted Date: 2014-12-23

Last Posted Date: 2020-03-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT02322190

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors

Phase 1

Completed

Conditions: Malignant Digestive System Neoplasm

Interventions: Drug: Alisertib
Drug: Fluorouracil
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Oxaliplatin

First Posted Date: 2014-12-18

Last Posted Date: 2018-10-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT02319018

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States

and more 2 locations

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Phase 1

Completed

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Talazoparib

First Posted Date: 2014-12-17

Last Posted Date: 2023-08-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT02317874

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Self-Affirmation and Defensiveness to Health Messages for the Self vs. a Close Other

Completed

Conditions: Social Science
Ego
Cancer Prevention

First Posted Date: 2014-12-16

Last Posted Date: 2018-09-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1019

Registration Number: NCT02317380

Locations: 🇺🇸
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States

Self-Affirmation: Construct Validity

Completed

Conditions: Risk Reduction Behavior

First Posted Date: 2014-12-16

Last Posted Date: 2021-08-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3112

Registration Number: NCT02317367

Locations: 🇺🇸
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

Conditions: Hematologic Malignancies
Pediatric Cancers
Solid Tumors

Interventions: Drug: anti-CD19 CAR

First Posted Date: 2014-12-12

Last Posted Date: 2025-03-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT02315599

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

Phase 1

Completed

Conditions: Large Cell Lymphoma
ALL
Acute Lymphocytic Leukemia
B-All
B-precursor ALL
Acute Lymphoblastic Leukemia
NHL
Follicular Lymphoma
B-Non Hodgkin Lymphoma
B-NHL

Interventions: Biological: CD22-CAR

First Posted Date: 2014-12-12

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 134

Registration Number: NCT02315612

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Phase 2

Terminated

Conditions: Neuroendocrine Tumors
Neuroendocrine Neoplasms
Carcinoma, Neuroendocrine
Neuroendocrine Carcinoma
Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas

Interventions: Drug: Sunitinib
Drug: Everolimus

First Posted Date: 2014-12-12

Last Posted Date: 2020-09-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT02315625

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Clear Cell Adenocarcinoma
Ovarian Clear Cell Adenocarcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Drug: Cabozantinib S-malate
Other: Laboratory Biomarker Analysis

First Posted Date: 2014-12-11

Last Posted Date: 2020-03-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT02315430

Locations: 🇺🇸
Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States
🇺🇸
Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸
Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States

and more 405 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy